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Extrapolating Parametric Survival Models in
Health Technology Assessment Using Model
Averaging: A Simulation Study
Daniel Gallacher , Peter Kimani , and Nigel Stallard
Previous work examined the suitability of relying on routine methods of model selection when extrapolating survival
data in a health technology appraisal setting. Here we explore solutions to improve reliability of restricted mean sur-
vival time (RMST) estimates from trial data by assessing model plausibility and implementing model averaging. We
compare our previous methods of selecting a model for extrapolation using the Akaike information criterion (AIC)
and Bayesian information criterion (BIC). Our methods of model averaging include using equal weighting across
models falling within established threshold ranges for AIC and BIC and using BIC-based weighted averages. We
apply our plausibility assessment and implement model averaging to the output of our previous simulations, where
10,000 runs of 12 trial-based scenarios were examined. We demonstrate that removing implausible models from con-
sideration reduces the mean squared error associated with the restricted mean survival time (RMST) estimate from
each selection method and increases the percentage of RMST estimates that were within 10% of the RMST from the
parameters of the sampling distribution. The methods of averaging were superior to selecting a single optimal extra-
polation, aside from some of the exponential scenarios where BIC already selected the exponential model. The
averaging methods with wide criterion-based thresholds outperformed BIC-weighted averaging in the majority of sce-
narios. We conclude that model averaging approaches should feature more widely in the appraisal of health technolo-
gies where extrapolation is influential and considerable uncertainty is present. Where data demonstrate complicated
underlying hazard rates, funders should account for the additional uncertainty associated with these extrapolations
in their decision making. Extended follow-up from trials should be encouraged and used to review prices of therapies
to ensure a fair price is paid.
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It is common for institutions responsible for selecting
interventions for reimbursement within a public health
care system, such as the National Institute for Health
and Care Excellence (NICE) in England and Wales, to
request an economic assessment of the intervention
across the lifetime of patients eligible for the indication
to establish whether it is likely to offer cost-effective ben-
efits. Depending on disease type and stage, patients may
be expected to live for decades after beginning their
course of therapy. Hence, to model the benefits of a
treatment across the patient lifetime, it is necessary to
make predictions of treatment efficacy across periods
where there are no observed data, as it is not in anyone’s
interest to wait years before these treatments become
part of routine care. This is more common as diseases
are detected earlier and medical technologies advance,
meaning phase III trials are becoming decreasingly
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informative to the decision maker who is interested in
this lifetime benefit. Since the price that NICE is willing
to pay for an intervention depends on the expected bene-
fit to patients, it is imperative to estimate these benefits
fairly across appraisals before proceeding with pricing
negotiations. This increases the importance of accurately
predicting patients’ future health as these predictions
become increasingly influential in the decision making
process, relative to periods where there are observed
data.
For many diseases, time-to-event outcomes, such as
death, are of critical interest to the decision maker, affect-
ing both the clinical and cost-effectiveness conclusions.
Time-to-event outcomes are routinely modeled in health
technology appraisals by fitting parametric models to
observed data and extrapolating until no patients are pre-
dicted to remain at risk of an event.1,2 These models are
commonly used to predict the amount of time patients
spend in particular health states, either through the esti-
mation of transition probabilities or mean survival times,
depending on the type of economic model. The time in
each health state is combined with a health-related
quality-of-life utility value and the costs of factors includ-
ing therapy, disease management, and adverse events to
produce an overall estimate of the cost-effectiveness of a
treatment relative to a comparator.
Previously, we have published a detailed simulation
study, which demonstrated the unreliability of extrapola-
tion with parametric models when estimating restricted
mean survival time (RMST) and the dangers of selecting
an incorrect model.3 Briefly, our simulation study repli-
cated time-to-event data from 4 phase III trials that were
pivotal in their relevant NICE technology appraisals.
Based on each trial, we simulated time-to-event data
from 3 source distributions and then fitted 8 parametric
curves and compared the RMST of models preferred by
the Akaike information criterion (AIC), Bayesian infor-
mation criterion (BIC), and log-likelihood. We showed
how overreliance on information criterion or the log-
likelihood for the selection of a single parametric model
is associated with bias and high uncertainty. However,
this work did not consider the plausibility of candidate
models and did not explore solutions to improve current
practice. AIC and BIC do not describe absolute good-
ness of fit but relative goodness of fit between the group
of candidate models. They cannot describe whether a
model fits well but that it is the best-fitting model from
those considered after accounting for model complexity.
Here we explore solutions to improve the reliability of
RMST estimates using model averaging, after first con-
sidering the plausibility of models, to increase the applic-
ability of our results.
The appropriateness of model averaging has been dis-
cussed.4 Previous work has extrapolated survival models
using Bayesian model averaging (BMA). Studies have
either considered averaging across candidate models
weighted using posterior model probabilities5 or also
included external data into the modeling.6,7 Model aver-
aging has not been considered in the specific setting of
RMST estimation, and we are unaware of any NICE
technology appraisals that used BMA. While the reasons
for this are unclear, we believe there may be resistance or
reluctance due to the perceived complexity of BMA. We
contrast the performance of BMA against our proposed
approach using evenly weighted estimates from the best-
fitting models. We chose our method of averaging as it
avoids the limitation of BMA where the best-fitting mod-
els can be given a very high weighting in comparison to
the candidate models and dominate the model averaging.
For example, applying BMA to 2 candidate models with
a difference in BIC of 5 units would result in the better-
fitting model receiving a weighting of 92.4%. If the best-
fitting model is not representative of the true behavior,
then this approach would result in an inaccurate extrapo-
lation. Our proposed approach of using equal weighting
reduces the chance of this happening. While still focusing
on the best-fitting models, this approach acknowledges
that among these models, it is often unclear which pro-
vides the most accurate prediction. This approach has
previously been described as ‘‘Occam’s window,’’8 or
‘‘forecast pooling,’’9 and applied in other areas, but we
believe this to be a novel application focused on the esti-
mation of RMST.
Methods
Our simulation study is described in more detail in our pre-
vious publication.3 Briefly, an exponential, a Weibull, and
a generalized gamma model were each fitted to re-created
patient-level data from clinical trials of 4 novel therapies
(dacomitinib, pembrolizumab, pertuzumab, and veneto-
clax) that were pivotal in their respective NICE technology
appraisals for specific indications10–14 to estimate a total of
12 sets of parameters, each corresponding to a distinct sce-
nario. The data were digitized using the Guyot method.15
Random sampling using each set of parameters and their
corresponding distribution generated a complete set of
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event time data for each of the 12 scenarios. The follow-up
of the dacomitinib and pembrolizumab trials could be con-
sidered mature, with the studies achieving their median
event time, while the pertuzumab and venetoclax trials
were considerably less mature. To replicate the follow-up
of each trial at their initial appraisal, censoring was mod-
eled using trial-specific parameters. Each scenario was
simulated 10,000 times and models were fitted using the
flexsurv package in R.16
We sought to explore alternative approaches to select-
ing a single extrapolation and considered methods of
model averaging. However, it was important to consider
the role of model plausibility to increase the applicability
of our study.
In a technology appraisal, the plausibility of models is
usually assessed by examination of the proportions of
patients predicted event free at certain milestones of
follow-up by each model, for example, the number of
patients remaining alive at 5 or 10 years from the begin-
ning of the trial. These predictions are compared to rele-
vant external studies with longer follow-up or to the
opinions of clinical experts, which may be presented as
point estimates or plausible ranges. As such information
was unobtainable for each of our 12 plausible yet hypothe-
tical scenarios, we replicated the assessment of plausibility
through comparison of the estimated RMST from each
model to the RMST calculated from the underlying distri-
bution used to generate the data. Three thresholds of per-
centage difference from the underlying RMST were used
to capture varying degrees of certainty that an investigator
may have in their prediction of unobserved treatment effi-
cacy. All models that produced RMST estimates outside
of these thresholds were excluded from consideration by
the methods of model selection. If all 8 models for a single
run were deemed implausible, then that run was excluded
from all analyses. A threshold of 650% reflected scenarios
where there is high uncertainty in the long term efficacy of
a treatment. A threshold of 625% represented moderate
uncertainty and 615% of where there is quite strong cer-
tainty. We compared AIC and BIC of all ‘‘plausible’’ mod-
els and selected the optimal model according to each
criterion. The outcome of interest was the RMST of the
preferred models in each simulation. We compared the
methods of single model selection following the applica-
tion of each plausibility threshold.
In seeking an alternative to relying on an RMST esti-
mate from a single curve, we considered different
approaches to combining estimates from multiple mod-
els. We chose to carry forward 2 sets of models to apply
our averaging methods: the first without any plausibility
assessment and the second using the 25% plausibility
threshold. The 25% threshold was chosen through a
comparison of the 4 scenarios generated by exponential
data-generating mechanisms. We compared the hazard
rates and survival predictions corresponding to each of
the RSMTs and their corresponding 615%/25%/50%
RMST estimates (Table 1). The 25% RMST threshold
was most consistent with the level of clinical certainty
and variation in survival predictions in NICE technology
appraisals from the authors’ years of experience of work-
ing alongside clinical experts in providing independent
critique on company submissions to NICE.
Our novel application of averaging involved averaging
across the best-fitting models as identified by AIC and
Table 1 Demonstration of the Relationship between the Differences in Mean Survival, the Hazard Rates, and the Survival Point


















Dacomitinib 4.24 0.0197 0.493 0.307 0.094
215% mean survival 3.60 0.0231 0.435 0.106 0.249 0.109 0.062 0.066
+15% mean survival 4.87 0.0171 0.540 0.358 0.128
225% mean survival 3.18 0.0262 0.389 0.179 0.207 0.182 0.043 0.108
+25% mean survival 5.30 0.0157 0.568 0.389 0.151
250% mean survival 2.12 0.0393 0.243 0.381 0.094 0.361 0.009 0.198
+50% mean survival 6.36 0.0131 0.624 0.455 0.207
Venetoclax 14.12 0.0059 0.809 0.702 0.492
215% mean survival 12.00 0.0070 0.779 0.052 0.659 0.076 0.435 0.106
+15% mean survival 16.23 0.0051 0.831 0.735 0.540
225% mean survival 10.59 0.0079 0.753 0.090 0.624 0.130 0.389 0.179
+25% mean survival 17.65 0.0047 0.844 0.753 0.567
250% mean survival 7.06 0.0118 0.654 0.214 0.492 0.297 0.242 0.381
+50% mean survival 21.18 0.0039 0.868 0.790 0.624
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BIC. We used established thresholds for AIC and BIC,
which are described as either including or ruling out
models with substantial support/considerably less sup-
port/no support (AIC)17 or positive/strong/very strong
differences from the best-fitting model (BIC). The corre-
sponding unit differences from the model with the lowest
criterion were \2, \7, and \10 units for AIC17 and
\2, \6, and \10 units for BIC.18 For each difference,
we identified all models whose criterion scores fell out-
side the range and excluded them from the RMST esti-
mation. All included models were given equal weighting
as we calculated their mean average RMST from their
estimates. The 2 methods of model selection combined
with the 3 unit differences yielded 6 averaging methods.
The general form of the weights, where P(kjy) is the
probability assigned to model k given data y such that
Pnp
k = 1
P kjyð Þ= 1, is given by
P kjyð Þ= 1
np
where np is the number of plausible models.
An alternative approach is to use weights based on the
BIC, instead of using equal weights. We generated the
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where dk is the difference between the BIC of model k
and the lowest BIC of the candidate models.19 Kass and
Raftery20 have shown that BIC approximates Bayes fac-
tors as used in BMA but is obtained without specification
of prior distributions. Hence, we refer to this method in
our results and discussion as ‘‘BMA’’ to avoid confusion
with the other averaging methods. We also explored tak-
ing the average of all models and weighting the RMST
estimates equally, both before and after application of
the 25% plausibility threshold.
The performance of each method was assessed through
the mean RMST estimate. Mean squared error (MSE),
Monte Carlo standard error (MCSE) and mean empirical
standard errors (EmpSE) were also measured. We also
captured the percentage of estimates that fell within 10%
of the RMST of the source distribution for each scenario.
Finally, we tested the performance of the novel aver-
aging methods and BMA when the prediction for RMST
on which we then verified plausibility was either 10%
under or over the actual RMST.
Our methods are summarized in Table 2 following
ADEMP (aims, data-generating mechanisms, estimands,
methods and performance measures) guidelines for report-
ing of simulations.21
Results
The relationship between the RMST plausibility thresh-
old and the exponential rate parameters and survival rate
point estimates at 3, 5, and 10 years for the exponential
Table 2 Trial Summary According to ADEMP Guidelines21
ADEMP Category Response
Aims To investigate whether considering model plausibility improved the suitability of the
methods of model selection and to examine whether methods of model averaging
improved the reliability of RMST estimates
Data-generating mechanism Data were repeatedly sampled from exponential, Weibull, and generalized gamma
distributions using parameters estimated from fitting models to re-created data from
4 phase III trials using a frequentist framework.
Methods Data were censored using trial-specific parameters to replicate the maturity of data
when the technologies were considered for reimbursement. Eight parametric models
were fitted to the data and their RMST estimates and goodness-of-fit statistics were
captured. The models preferred by each of AIC, BIC, and log-likelihood were
compared. Model plausibility was assessed by whether their RMST estimates were
within 50%, 25%, or 15% of the RMST from the sampling distribution. Model
averaging methods were applied to models deemed plausible at the 25% threshold,
using established thresholds for AIC and BIC.
Estimand RMST
Performance measures Bias, empirical standard error, mean squared error, Monte-Carlo standard error
ADEMPT, aims, data-generating mechanisms, estimands, methods and performance measures, AIC, Akaike information criterion; BIC, Bayes
information criterion; RMST, restricted mean survival time.
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dacomitinib and venetoclax scenarios is shown in Table 1.
The 25% threshold was associated with an interval of width
13 and 18 percentage units around the target survival rates
at 5 years, and an interval of 11 to 18 percentage units at 10
years. The estimates coming from the 650% difference in
RMST yielded implausibly wide intervals.
Supplementary Table S1 shows the number of model
fits excluded at each of the plausibility thresholds, where
some model fits were excluded a large number of times in
certain scenarios. The log-logistic and log-normal models
especially struggled to provide estimates of RMST that
were consistent with the underlying distributions in the
scenarios considered, but all models faced high exclusion
rates in certain scenarios. Despite the occasional large
number of excluded models, only the pembrolizumab
generalized gamma scenario with the 25% and 15%
thresholds had more than 5% of simulation runs with no
plausible models included, with ; 25% and ; 50% of
respective runs excluded. In the generalized gamma sce-
narios, selecting a generalized gamma extrapolation pro-
duced estimates within 15% of the true RMST value in
30% (pertuzumab) to 73% (dacomitinib) of simulations
and within 25% of the true RMST value in 52% (pertu-
zumab) to 86% (dacomitinib) of simulations.
Supplementary Table S2 shows the results for the
methods of single model selection at each plausibility
threshold. The MSE, MCSE, and EmpSE associated with
each selection method decreased as the threshold became
tighter. In all scenarios that used an exponential source
distribution, models preferred by BIC were associated with
the lowest MSE regardless of the plausibility threshold
used. Weibull and generalized gamma-based scenarios
with thresholds applied were more varied, with each of the
3 methods having the lowest MSE on multiple occasions.
However, BIC was most commonly associated with the
lowest MSE in 10 of 24 nonexponential scenarios, com-
pared to 8 for AIC and 5 for log-likelihood, with AIC and
BIC having the same MSE for 1 scenario.
Across each scenario, applying the 50% threshold had a
very small or even no impact on the percentage of RMST
estimates that fell within 10% of the true RMST, despite
large numbers of particular curves being excluded. Larger
impacts were seen when the tighter thresholds were applied.
The results of the different approaches to model aver-
aging without any assessment of plausibility are shown
in Figure 1 and Supplementary Table S3. A comparison
of the best-performing method of averaging from
Supplementary Table S3 to the best-performing method
of selecting a single model without considering plausibil-
ity suggested that model averaging without considering
plausibility did not reduce bias in any scenarios and
noticeably increased it on 2 occasions (Figure 1E,F).
The optimal method of averaging was almost always
superior to the optimal method of single model selection
when assessing MSE and EmpSE and never inferior.
Interestingly, when comparing the percentage of esti-
mates falling within 10% of the true RMST, averaging
was superior in 4 scenarios (all venetoclax or pertuzu-
mab scenarios; Figure 1H,I,K,L), inferior in 4 scenarios
(Figure 1C,D,E,J), and with no meaningful difference in
4 scenarios (Figure 1A,B,F,G), suggesting the benefits of
model averaging are stronger when data are immature
and demonstrate a nonconstant hazard rate.
Comparing the performance of the nonoptimal meth-
ods of single model selection to their associated methods
of averaging methods found that averaging across a
range of models either reduced or had no impact on bias
and improved MSE and EmpSE estimates. The effect of
averaging on the percentage of estimates falling within
10% of the true RMST was again mixed.
Within the methods of averaging without considering
plausibility, information criterion–based averaging had
the lowest MSE in 6 scenarios (Figure 1A–E,J), with all
but one of these coming from pembrolizumab and daco-
mitinib scenarios. In all other scenarios, averaging
equally across all models was associated with the lowest
MSE (Figure 1F–I,K,L). BMA did not have the lowest
MSE in any of these scenarios.
The outcomes of the averaging methods after the
assessment for plausibility are presented in Figure 2 and
Supplementary Table S4. Contrasting the performance
of the best averaging method to the optimal method of
selecting a single model with considering plausibility sug-
gested that model averaging had no effect on bias.
However, in most scenarios, the best averaging method
was associated with lower MSE, lower EmpSE, and a
higher percentage of models falling within 10% of the true
RMST compared to the optimal method of single model
selection. The nonoptimal methods of single model selec-
tion were all either equaled or outperformed by their asso-
ciated methods of model averaging, in terms reducing
each of bias, MSE, and EmpSE and increasing the per-
centage of estimates falling within 10% of the true RMST.
The scenarios with the lowest percentage of estimates
falling within 10% of the true RMST when choosing a
single model were the generalized gamma scenarios of
pembrolizumab (39%) (Figure 2F) and pertuzumab
(34%) (Figure 2I). Averaging across all plausible models
increased these to 45% and 69%, respectively.
Examination of the different approaches to averaging
following the removal of implausible models suggests
that taking the mean RMST of all plausible models pro-
duced estimates that had the least bias and lowest MSE
and EmpSE, although these were often all similar to the





























































































































































































































































































































































































































































averaging methods based on AIC and BIC when using
the widest margins of inclusivity. Averaging across all
plausible models was associated with the lowest MSE in
9 of 12 scenarios (Figure 2A–C,E,F,H,I,K,L), even
including the methods of single model selection.
In 3 of the 4 exponential scenarios, both BMA and
averaging across models with the smallest BIC margin
were associated with RMST estimates that had the lowest
MSE (Figure 2D,G,J) and 2 of these also with the lowest
EmpSE and the highest percentage of estimates falling
within 10% of the true RMST (Figure 2G,J). Across the
12 scenarios, the wider AIC and BIC (7, 6, 10, and 10
units) threshold-based methods had a lower MSE than
BMA in 9, 8, 9, and 9 scenarios, respectively.
The optimal single model selection method for the
pembrolizumab generalized gamma scenario (Figure 2I)
had the lowest percentage of RMST estimates that fell
within 10% of the target RMST of all scenarios (15%).
The optimal averaging approach raised this to 58%. The
scenario with the highest percentage of estimates falling
within 10% from the best single model selection method
was 93% in the exponential pertuzumab scenario (Figure
2G), whereas the corresponding estimate for the optimal
averaging method was 91%.
Our analyses of scenarios where the 25% plausibility
threshold was based on an incorrect estimate of the
underlying RMST showed that the methods of averaging
were equivalent or superior to the optimal method of sin-
gle model selection across all Weibull and generalized
gamma scenarios but worse for the exponential scenarios
(Supplementary Tables S5–S7). Averaging across all
plausible models was robust to underestimation of
RMST, but this method was usually outperformed by an
averaging method based on information criterion when
RMST was overestimated.
Discussion
In this study, we have implemented solutions that improve
reliability and accuracy when estimating RMST than
relying on single model methods, comparing different
approaches to model averaging after first removing
implausible models. We have presented results for a
range of scenarios that capture combinations of varying
sample sizes, hazard rates, hazard shapes, and durations
of follow-up. The scenarios replicate the data considered
by decision makers such as NICE and capture the associ-
ated challenges these decision makers face, ensuring our
findings are relevant to current practice.
Considering first model plausibility, the high exclu-
sion rate of the log-normal and log-logistic models
emphasizes the clear difference in characteristics between
the models, reinforcing the findings from our previous
study.3 Similarly, the models with the most parameters
(generalized gamma and generalized F) also showed high
exclusion rates, suggesting these more flexible models are
prone to overfit to data and cannot be relied upon to
provide accurate extrapolations in all circumstances. If
we instead used the log-normal or log-logistic models as
source distributions, then we would anticipate a similar
degree of exclusion for the some of the other parametric
models.
While it is reassuring to see that in almost all scenar-
ios, it was rare for a whole simulation run to be excluded
for a lack of plausible extrapolations, the pembrolizu-
mab generalized gamma scenario demonstrated that
there are times when the observed data are not sufficient
to allow a model to reliably capture the intricate hazard
rate behavior. If hazard rate behavior is expected to be
more complicated than that of a 2-parameter model (i.e.,
all 2-parameter models fit poorly), the decision maker
should account for the increased uncertainty associated
with the extrapolations of 3- and 4-parameter models.
Removing implausible models often had a consider-
able impact on reducing the MSE of models preferred by
each of the selection methods, even under our widest
plausibility threshold. However, the impact on the per-
centage of extrapolations falling within 10% of the
underlying RMST was minimal, suggesting that the most
implausible curves were rarely favored by the selection
methods. After excluding at the 50% and 25% plausibil-
ity thresholds, this percentage varied greatly across the
different scenarios and remained as low as 34% in the
pertuzumab generalized gamma scenario after the 25%
threshold was applied. Hence, relying on the exclusion of
the most implausible models would not guarantee a reli-
able RMST estimate, and we continued to investigate
the potential benefits of model averaging.
Methods of model averaging do not feature regularly
in NICE technology appraisals, perhaps due to the per-
ceived complexity in their implementation and in com-
municating their technical details to an appraisal
committee. This led to our consideration of simpler alter-
natives, which we aligned with the established thresholds
for AIC and BIC.
We showed that averaging across plausible models
never increased bias or MSE and did not decrease the
percentage of estimates falling within 10% of the under-
lying RMST compared to when just a single model is
selected, suggesting that model averaging can improve
the quality of extrapolations in technology assessments.
Implementation of this approach assumes there is no dis-
agreement over the identification of plausible models.
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There remain occasions, such as the generalized
gamma pembrolizumab scenario, where no methods reli-
ably produced an accurate estimate of RMST. It raises
the question of whether it is right to base funding deci-
sions on extrapolations in cases where there is an appar-
ent change in hazard rate behavior in the tail of the data,
perhaps supported by clinical plausibility, which is
unlikely to be accurately captured by a statistical model.
The methods generally performed worse when the data
were either immature or coming from a more compli-
cated underlying distribution. Certainly, stakeholders
should be aware of which scenarios are associated with
increased uncertainty, and pharmaceutical companies
should consider these uncertainties when entering pricing
negotiations. The more complex the underlying distribu-
tion, the less likely it is to be accurately captured by the
models. In the scenarios using a generalized gamma–
based data-generating mechanism, the variation in the
fitted generalized gamma models was very high. If data
are immature or the company is putting forward a multi-
parameter model, it cannot expect the health care provi-
der to bear all the risks and should anticipate more
caution from the decision maker.
An alternative approach could be based only on
observed benefits, perhaps combined with pricing revi-
sions once longer follow-up is achieved, which may result
in better value for the healthcare provider. If both the
buyer and the seller accepted that these revisions could
shift the price in either direction, then the risks are effec-
tively shared and ensure that the price is based on the
efficacy of a treatment. It is vital that long-term follow-
up and routine data such as registries are available to
those involved in the decision making process. The
Cancer Drugs Fund in England is an example of a
scheme where patients are granted access to therapy for
treatments that have the potential to be cost-effective,
while more data are collected prior to a concluding
appraisal.
The benefit gained from excluding implausible models
was meaningful, which demonstrates that the plausibility
of models is an important consideration and that the
weighting applied by BMA was insufficient at reducing
the influence of inappropriate models. BMA was gener-
ally outperformed by the simpler approaches to averages,
using the established margins around the AIC and BIC
of the models with the lowest criteria for each measure.
This simpler approach may be welcomed more readily by
appraisal committees when there is uncertainty over the
optimal extrapolation. The general superiority of the
wider intervals suggests a most inclusive approach should
be taken when averaging, once implausible models have
been removed. Of course, in practice, it is often difficult
to reach a consensus on what should be considered plau-
sible. It would be difficult to give general guidance as it is
important to capture input from relevant clinical experts.
The efficacy of all averaging methods depends on the
suitability of the candidate models across which the aver-
age is estimated. The set of candidate models being con-
sidered could be thought of as a prior, that is, the belief
that the truth lies within or between this set of models.
Considering 8 parametric models gives us a range of
options but does not guarantee that any of the models
will accurately capture observed behavior or yield a plau-
sible prediction.
It is difficult to compare our assessment of extrapola-
tion plausibility, which is using differences from the
underlying RMST, to a real-world assessment of plausi-
bility. Every technology appraisal would have a different
combination of trial follow-up, patient prognosis, and
external points of reference to compare extrapolations.
Predictions from clinical experts have no guarantee over
their accuracy. Our widest threshold would be represen-
tative of occasions when there is only little to no evidence
of what a plausible extrapolation might be, with only
plainly wrong extrapolations being excluded, whereas the
smallest threshold would be more representative of when
relevant evidence is available.
All scenarios considered were generated from a single
underlying parametric model. These results may not be
generalizable to occasions when models fit poorly to data,
where either modeling of distinct subgroups or flexible
parametric approaches may be necessary. Further studies
should aim to generate survival data with more complex
hazard rates, perhaps sampling from a combination of
parametric distributions, to investigate how the parametric
models, the methods of model selection, and the methods
of model averaging all perform when the underlying distri-
bution is not necessarily present in the candidate models.
We have considered data only from single arms of
studies and not included comparators or investigated
how these findings might influence a subsequent cost-
effectiveness analysis. Additional work is needed to inves-
tigate whether the bias and uncertainty detected in these
simulations may work in favor of a novel intervention
and the pharmaceutical company. Only 4 combinations
of sample size, event rate, and follow-up length were con-
sidered in this simulation study. It is possible our findings
may not extend to different combinations of these factors
affecting extrapolations. Parametric extrapolations, even
with averaging, will never be a substitute for mature fol-
low-up, which only extended follow-up beyond achieve-
ment of primary outcomes of clinical trials will provide.
While institutions such as NICE continue to assess cost-
effectiveness based on the lifetime efficacy, it is important
Gallacher et al. 483
for all stakeholders that uncertainty is minimized in these
predictions without relying on statistical predictions. This
will ensure fair pricing and access to treatments.
Conclusion
We conclude that it is helpful to assess plausibility of
extrapolations when selecting a model. We recommend
that methods of model averaging should be considered
more widely in health technology appraisals given their
clear benefit in most cases. The optimal method in the
majority of our scenarios was to take the mean average
of RMST predictions across all plausible models, without
using weights based on information criteria, but plausi-
bility in the real world will be subjective. There is no gui-
dance to decide on plausibility or on the most suitable
margin should averaging using information criterion–
based averaging be used. Averaging is not necessary
where the survival data are expected to resemble an expo-
nential distribution, and using averaging in these occa-
sions may reduce accuracy. Scenarios with complex
hazard behavior or immature data are associated with
greater uncertainty, which should be accounted for in the
decision making process. Funders should avoid commit-
ting to paying prices for treatments that are deemed cost-
effective from immature follow-up and should review
prices once extended follow-up is available, with initial
approval conditional on pharmaceutical companies pro-





Supplementary material for this article is available on the
Medical Decision Making website at http://journals.sagepub
.com/home/mdm.
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